Rheumatoid Arthritis Trial, Recruiting (NCT07517250)

Rheumatoid Arthritis Trial, Recruiting NCT07517250 Sponsor: Novartis Pharmaceuticals Condition: Rheumatoid Arthritis

Printed from Voxsanity (voxsanity.com.au) — NCT07517250 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rheumatoid Arthritis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People (children or adults) who were prescribed the medication canakinumab before October 2021 and took it for at least 6 months to treat a condition called FMF (Familial Mediterranean Fever) or Still's disease (which includes two forms known as SJIA and AOSD).
People for whom at least 3 years of medical records are available, covering details about their health and treatments from when they first started taking canakinumab.

Who may not be able to join:

People who were younger than 2 years old (under 24 months) at the time they started canakinumab treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Phone: +41613241111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07517250

Sponsor: Novartis Pharmaceuticals

Phase: Not Applicable

Status: Recruiting

Condition: Rheumatoid Arthritis

Trial contact: +41613241111

More information: https://clinicaltrials.gov/study/NCT07517250

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People (children or adults) who were prescribed the medication canakinumab before October 2021 and took it for at least 6 months to treat a condition called FMF (Familial Mediterranean Fever) or Still's disease (which includes two forms known as SJIA and AOSD).
People for whom at least 3 years of medical records are available, covering details about their health and treatments from when they first started taking canakinumab.

Who may not be able to join:

People who were younger than 2 years old (under 24 months) at the time they started canakinumab treatment.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Novartis Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

15 March 2026

Est. completion

3 December 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Percentage of Patients With Clinically Inactive Disease Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents; Percentage of Patients With Partial Remission Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents; Percentage of Patients With Complete Response Under Treatment With Canakinumab Received in First or Second or More Lines of Treatment With Biologic Agents; Percentage of Patients With Partial Response Under Treatment With Canakinumab Received in First or Second or More Lines of...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov